First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

On October 12th, 2026, First Tracks Biotherapeutics announced promising results from their recent Phase 1b clinical study of potential Celiac drug ANB033:

ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms

First Tracks also noted that ANB033 is “well-tolerated”, with no serious side effects reported so far.

The full press release can be read here.

Please keep in mind that these are very early, preliminary results. A lot more research, including larger-scale clinical trials, are needed before this treatment can be approved. Unfortunately, the vast majority of potential Celiac Disease treatments have not made it past Phase 2 (of 3) so far.

Bob’s Red Mill has changed their 1 to 1 Gluten Free Flour blend

You may have noticed recently that Bob’s Red Mill 1 to 1 Gluten Free Flour has a new look. . . and a somewhat different ingredient list.

The new blend replaces whole grain sorghum flour with white sorghum flour. It also contains a higher ratio of sorghum flour than the previous version did.

If you’ve used Bob’s Red Mill 1 to 1 in your gluten free baking, your recipes may now turn out differently with this updated blend.

Have you tried baking with the new Bob’s Red Mill 1 to 1 Gluten Free Flour? How did it turn out? Let us know in the comments!

Please Vote!

Northeast Ohio Celiac Network is a strictly nonpartisan organization. As a group, we do not endorse any specific candidates or political parties and we will not tell you how to vote.

That being said, we urge you to vote in the 2026 midterm elections by November 3rd. Your elected officials help determine if and how government funding is used for medical research, including Celiac Disease research. In addition, several pieces of legislation have been recently introduced in Congress that, if passed, would affect the labeling of gluten on the food or medication you buy. Your vote could help determine whether or not any of these bills become law. This is your chance to make your voice heard!

Early voting is already underway in Ohio. Find out how you can vote at https://www.ohiosos.gov/elections.

Here are the Celiac-related bills that Congress is currently considering:

H.R. 9048 – The Celiac Safety Act of 2026

If this bill becomes law, “gluten-containing grain” (defined as wheat, rye, barley, and their derivatives) would be added to the list of major allergens covered under the Food Allergen Labeling and Consumer Protection Act (FALCPA) that must be specifically called out on food ingredient labels. Wheat would still have be listed as a separate allergen.

H.R. 8385 – The Food Labeling Modernization Act of 2026

This bill, if passed, would require “gluten-containing grain” (defined as wheat, rye, barley, and their derivatives) to have the same labeling requirements as the allergens covered under FALCPA. But it does not define “gluten-containing grain” as an allergen. Wheat would still be defined as an allergen and specifically called out on food labels.

This legislation would also require ingredient, allergen, and nutrition information to be disclosed when food is sold online or on apps like Instacart and Doordash.

H.R. 9988 – The Food Allergy Safety, Treatment, Education, and Research (FASTER) Act of 2026

If passed, this bill would replace wheat with “gluten-containing grain” on the list of allergens covered by FALCPA. “Gluten-containing grain” on this bill includes wheat, rye, barley, oats, and their derivatives. This is the only currently proposed legislation that is trying to add oats to the major allergen list.

This bill would also require the Secretary of Health and Human Services to submit a report to Congress about Celiac Disease.

H.R. 3821 – Allergen Disclosure In Non-Food Articles (ADINA) Act

This bill, if passed, would require the labeling of allergens and gluten-containing grains in medications.

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

Exciting news in Celiac research! Potential Celiac Disease treatment FB102 is moving into Phase 3 trials after positive Phase 2 results!

https://argenx.com/news/2026/press-release-3376936

This treatment, if approved, would not eliminate the need for a gluten free diet, but it would offer some protection against gluten cross contact. I’m sure most of us would agree that would still be a huge game-changer.

Very few potential Celiac treatments have ever made it past Phase 2, so this is a very promising development.